Dr. Bryan Byong Jin Kim, President and CEO of VGX International (“VGXI”) has been named as the “Global CEO of Korea 2010” in the biotechnology enterprise sector. President Kim was awarded the ‘Biotechnology Enterprise Sector’ Award at the “Global CEO of Korea 2010” ceremony that was held at the Millennium Hilton Hotel on the 24th of August, 2010. It is a renowned event that was hosted by a monthly economic magazine, Forbes Korea, and sponsored by the Ministry of Knowledge Economy and JoongAng Daily. The award which is divided into 13 categories such as brand management, marketing management, BT management, R&D management, selects and awards global CEOs who have enhanced the global position of Korea. The award citation highlighted President Kim’s contribution on giving Korea a global competitiveness in the field of DNA vaccines. VGXI received approval for the H5N1 avian influenza prophylactic DNA vaccine (VGX-3400) by the Korean Food & Drug Administration (KFDA) for the first time in Asia on February of 2010, and on March, signed the “Collaboration and license Agreement” for the collaborative development of the universal influenza vaccine program which prevents the seasonal flu, pre-pandemic flu, and avian flu all at the same time. With this, President Kim’s management outcomes of securing a world-class DNA vaccine pipeline for influenza in Korea and consequently entering a phase I clinical trial have been highly acknowledged. 32 people were honored at this ceremony. VGXI, Inc., (“VGXII”) a wholly owned subsidiary CMO of VGX International where President Kim is also acting as President & CEO, was nominated as one of the top six global ‘Contract Manufacture Organization’ along with DSM, one of the three leading contract manufacture organization at the World Vaccine Congress that was held on April, 2010.